image credit: Freepik

FDA approves expanded use for Chiesi’s sickle cell drug Ferriprox

May 4, 2021


Ferriprox (deferiprone) is now approved in the US for the treatment of transfusional iron overload due to SCD or other anaemias in adult and paediatric patients aged three years or older.

The new approval expands the use of Ferriprox beyond its other indication, where it is approved to treat patients with transfusional iron overload due to thalassemia syndromes.

In the US, SCD affects approximately 100,000 people and is associated with a lower life expectancy of over 20 years compared with the general population.

Read More on PMLiVE